Open AccessA Standardized Plaque Reduction Assay for Determination of Drug Susceptibilities of Cytomegalovirus Clinical Isolates
Author(s) -
Marie L. Landry,
Sylvia C. Stanat,
Karen K. Biron,
Donald Brambilla,
William J. Britt,
Janet A. Jokela,
Sunwen Chou,
W. Lawrence Drew,
Alejo Erice,
Bruce L. Gilliam,
Nell S. Lurain,
Jody Manischewitz,
Richard C. Miner,
Mostafa Nokta,
Patricia Reichelderfer,
Stephen A. Spector,
Adriana Weinberg,
Belinda YenLieberman,
Clyde S. Crumpacker
Publication year - 2000
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.44.3.688-692.2000
Subject(s) - virus quantification , cytomegalovirus , virology , human cytomegalovirus , biology , drug , medicine , herpesviridae , virus , pharmacology , viral disease
Twelve laboratories collaborated in formulating and testing a standardized plaque reduction assay for cytomegalovirus (CMV) cell-associated clinical isolates. Four characterized and plaque-purified CMV strains, as well as six coded clinical isolates obtained after antiviral therapy, were distributed and tested. Good agreement was obtained for four of the clinical isolates, but a broad distribution of results was obtained for two isolates. Analysis of these results indicates the problems associated with clinical isolates, including the large genetic variability and the highly cell-associated phenotype. This collaborative effort, by addressing these problems, represents a significant step toward the development of a standardized assay.